Another hedge-fund-sponsored biopharmaceutical company has set its terms for going public.
Oric Pharmaceuticals said it plans to offer 6.3 million shares at between $14 and $16 per share. Earlier in the week it had filed plans to offer 5 million shares in the same price range.
Oric
